NYSE:TEVA

Teva Pharmaceutical Industries Competitors

$10.40
+0.11 (+1.07 %)
(As of 05/7/2021 12:00 AM ET)
Add
Compare
Today's Range
$10.21
$10.46
50-Day Range
$10.09
$11.93
52-Week Range
$8.44
$13.30
Volume6.18 million shs
Average Volume9.56 million shs
Market Capitalization$11.36 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.49

Competitors

Teva Pharmaceutical Industries (NYSE:TEVA) Vs. ALXN, BGNE, RPRX, GMAB, HZNP, and CVAC

Should you be buying TEVA stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Teva Pharmaceutical Industries, including Alexion Pharmaceuticals (ALXN), BeiGene (BGNE), Royalty Pharma (RPRX), Genmab A/S (GMAB), Horizon Therapeutics Public (HZNP), and CureVac (CVAC).

Teva Pharmaceutical Industries (NYSE:TEVA) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk and valuation.

Insider and Institutional Ownership

51.2% of Teva Pharmaceutical Industries shares are held by institutional investors. Comparatively, 87.3% of Alexion Pharmaceuticals shares are held by institutional investors. 0.6% of Teva Pharmaceutical Industries shares are held by insiders. Comparatively, 4.0% of Alexion Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Teva Pharmaceutical Industries and Alexion Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Teva Pharmaceutical Industries$16.89 billion0.67$-998,000,000.00$2.314.50
Alexion Pharmaceuticals$4.99 billion7.55$2.40 billion$9.7417.50

Alexion Pharmaceuticals has lower revenue, but higher earnings than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Teva Pharmaceutical Industries has a beta of 1.49, meaning that its stock price is 49% more volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Teva Pharmaceutical Industries and Alexion Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Teva Pharmaceutical Industries18302.17
Alexion Pharmaceuticals015402.21

Teva Pharmaceutical Industries presently has a consensus target price of $11.7778, indicating a potential upside of 13.25%. Alexion Pharmaceuticals has a consensus target price of $159.3158, indicating a potential downside of 6.52%. Given Teva Pharmaceutical Industries' higher possible upside, analysts plainly believe Teva Pharmaceutical Industries is more favorable than Alexion Pharmaceuticals.

Profitability

This table compares Teva Pharmaceutical Industries and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Teva Pharmaceutical Industries-24.17%19.32%4.89%
Alexion Pharmaceuticals16.32%23.16%14.76%

Summary

Alexion Pharmaceuticals beats Teva Pharmaceutical Industries on 11 of the 14 factors compared between the two stocks.

Teva Pharmaceutical Industries (NYSE:TEVA) and BeiGene (NASDAQ:BGNE) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings and analyst recommendations.

Insider & Institutional Ownership

51.2% of Teva Pharmaceutical Industries shares are held by institutional investors. Comparatively, 60.7% of BeiGene shares are held by institutional investors. 0.6% of Teva Pharmaceutical Industries shares are held by insiders. Comparatively, 9.0% of BeiGene shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Teva Pharmaceutical Industries and BeiGene's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Teva Pharmaceutical Industries$16.89 billion0.67$-998,000,000.00$2.314.50
BeiGene$428.21 million66.81$-948,630,000.00($15.80)-19.74

BeiGene has lower revenue, but higher earnings than Teva Pharmaceutical Industries. BeiGene is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Teva Pharmaceutical Industries has a beta of 1.49, suggesting that its share price is 49% more volatile than the S&P 500. Comparatively, BeiGene has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings for Teva Pharmaceutical Industries and BeiGene, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Teva Pharmaceutical Industries18302.17
BeiGene21602.44

Teva Pharmaceutical Industries presently has a consensus target price of $11.7778, indicating a potential upside of 13.25%. BeiGene has a consensus target price of $319.3750, indicating a potential upside of 2.37%. Given Teva Pharmaceutical Industries' higher possible upside, equities analysts plainly believe Teva Pharmaceutical Industries is more favorable than BeiGene.

Profitability

This table compares Teva Pharmaceutical Industries and BeiGene's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Teva Pharmaceutical Industries-24.17%19.32%4.89%
BeiGene-569.22%-56.81%-39.93%

Summary

Teva Pharmaceutical Industries beats BeiGene on 8 of the 14 factors compared between the two stocks.

Teva Pharmaceutical Industries (NYSE:TEVA) and Royalty Pharma (NASDAQ:RPRX) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings and analyst recommendations.

Insider & Institutional Ownership

51.2% of Teva Pharmaceutical Industries shares are held by institutional investors. Comparatively, 40.9% of Royalty Pharma shares are held by institutional investors. 0.6% of Teva Pharmaceutical Industries shares are held by insiders. Comparatively, 2.5% of Royalty Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings for Teva Pharmaceutical Industries and Royalty Pharma, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Teva Pharmaceutical Industries18302.17
Royalty Pharma05402.44

Teva Pharmaceutical Industries presently has a consensus target price of $11.7778, indicating a potential upside of 13.25%. Royalty Pharma has a consensus target price of $51.8750, indicating a potential upside of 26.62%. Given Royalty Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Royalty Pharma is more favorable than Teva Pharmaceutical Industries.

Profitability

This table compares Teva Pharmaceutical Industries and Royalty Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Teva Pharmaceutical Industries-24.17%19.32%4.89%
Royalty PharmaN/AN/AN/A

Earnings and Valuation

This table compares Teva Pharmaceutical Industries and Royalty Pharma's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Teva Pharmaceutical Industries$16.89 billion0.67$-998,000,000.00$2.314.50
Royalty PharmaN/AN/AN/AN/AN/A

Royalty Pharma has lower revenue, but higher earnings than Teva Pharmaceutical Industries.

Summary

Royalty Pharma beats Teva Pharmaceutical Industries on 5 of the 9 factors compared between the two stocks.

Genmab A/S (NASDAQ:GMAB) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, risk, profitability, analyst recommendations and valuation.

Insider & Institutional Ownership

6.2% of Genmab A/S shares are held by institutional investors. Comparatively, 51.2% of Teva Pharmaceutical Industries shares are held by institutional investors. 0.6% of Teva Pharmaceutical Industries shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current recommendations and price targets for Genmab A/S and Teva Pharmaceutical Industries, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Genmab A/S24902.47
Teva Pharmaceutical Industries18302.17

Genmab A/S currently has a consensus price target of $41.5714, indicating a potential upside of 11.15%. Teva Pharmaceutical Industries has a consensus price target of $11.7778, indicating a potential upside of 13.25%. Given Teva Pharmaceutical Industries' higher possible upside, analysts clearly believe Teva Pharmaceutical Industries is more favorable than Genmab A/S.

Profitability

This table compares Genmab A/S and Teva Pharmaceutical Industries' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Genmab A/S50.99%34.40%30.67%
Teva Pharmaceutical Industries-24.17%19.32%4.89%

Volatility & Risk

Genmab A/S has a beta of 0.93, indicating that its share price is 7% less volatile than the S&P 500. Comparatively, Teva Pharmaceutical Industries has a beta of 1.49, indicating that its share price is 49% more volatile than the S&P 500.

Earnings & Valuation

This table compares Genmab A/S and Teva Pharmaceutical Industries' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genmab A/S$804.57 million30.49$324.68 million$0.5173.33
Teva Pharmaceutical Industries$16.89 billion0.67$-998,000,000.00$2.314.50

Genmab A/S has higher earnings, but lower revenue than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Summary

Genmab A/S beats Teva Pharmaceutical Industries on 8 of the 14 factors compared between the two stocks.

Horizon Therapeutics Public (NASDAQ:HZNP) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, risk, profitability, analyst recommendations and valuation.

Insider & Institutional Ownership

88.6% of Horizon Therapeutics Public shares are held by institutional investors. Comparatively, 51.2% of Teva Pharmaceutical Industries shares are held by institutional investors. 4.3% of Horizon Therapeutics Public shares are held by company insiders. Comparatively, 0.6% of Teva Pharmaceutical Industries shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current recommendations and price targets for Horizon Therapeutics Public and Teva Pharmaceutical Industries, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Horizon Therapeutics Public001103.00
Teva Pharmaceutical Industries18302.17

Horizon Therapeutics Public currently has a consensus price target of $111.3636, indicating a potential upside of 26.65%. Teva Pharmaceutical Industries has a consensus price target of $11.7778, indicating a potential upside of 13.25%. Given Horizon Therapeutics Public's stronger consensus rating and higher possible upside, research analysts clearly believe Horizon Therapeutics Public is more favorable than Teva Pharmaceutical Industries.

Profitability

This table compares Horizon Therapeutics Public and Teva Pharmaceutical Industries' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Horizon Therapeutics Public43.55%25.66%14.19%
Teva Pharmaceutical Industries-24.17%19.32%4.89%

Volatility & Risk

Horizon Therapeutics Public has a beta of 1.15, indicating that its share price is 15% more volatile than the S&P 500. Comparatively, Teva Pharmaceutical Industries has a beta of 1.49, indicating that its share price is 49% more volatile than the S&P 500.

Earnings & Valuation

This table compares Horizon Therapeutics Public and Teva Pharmaceutical Industries' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Horizon Therapeutics Public$1.30 billion15.16$573.02 million$1.9445.32
Teva Pharmaceutical Industries$16.89 billion0.67$-998,000,000.00$2.314.50

Horizon Therapeutics Public has higher earnings, but lower revenue than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Horizon Therapeutics Public, indicating that it is currently the more affordable of the two stocks.

Summary

Horizon Therapeutics Public beats Teva Pharmaceutical Industries on 11 of the 14 factors compared between the two stocks.

CureVac (NASDAQ:CVAC) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, risk, profitability, analyst recommendations and valuation.

Insider & Institutional Ownership

4.3% of CureVac shares are held by institutional investors. Comparatively, 51.2% of Teva Pharmaceutical Industries shares are held by institutional investors. 0.6% of Teva Pharmaceutical Industries shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current recommendations and price targets for CureVac and Teva Pharmaceutical Industries, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CureVac11302.40
Teva Pharmaceutical Industries18302.17

CureVac currently has a consensus price target of $58.3333, indicating a potential downside of 41.90%. Teva Pharmaceutical Industries has a consensus price target of $11.7778, indicating a potential upside of 13.25%. Given Teva Pharmaceutical Industries' higher possible upside, analysts clearly believe Teva Pharmaceutical Industries is more favorable than CureVac.

Profitability

This table compares CureVac and Teva Pharmaceutical Industries' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CureVacN/AN/AN/A
Teva Pharmaceutical Industries-24.17%19.32%4.89%

Earnings & Valuation

This table compares CureVac and Teva Pharmaceutical Industries' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CureVacN/AN/AN/AN/AN/A
Teva Pharmaceutical Industries$16.89 billion0.67$-998,000,000.00$2.314.50

CureVac has higher earnings, but lower revenue than Teva Pharmaceutical Industries.

Summary

Teva Pharmaceutical Industries beats CureVac on 6 of the 8 factors compared between the two stocks.


Teva Pharmaceutical Industries Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.7$170.43+0.3%$37.67 billion$4.99 billion39.82Analyst Upgrade
Analyst Revision
BeiGene logo
BGNE
BeiGene
1.1$311.97+0.7%$28.61 billion$428.21 million-15.44Earnings Announcement
Insider Selling
Analyst Revision
News Coverage
Gap Up
Royalty Pharma logo
RPRX
Royalty Pharma
1.9$40.97+0.2%$24.87 billionN/A0.00Upcoming Earnings
News Coverage
Genmab A/S logo
GMAB
Genmab A/S
1.4$37.40+0.5%$24.53 billion$804.57 million28.99Earnings Announcement
Analyst Revision
News Coverage
Horizon Therapeutics Public logo
HZNP
Horizon Therapeutics Public
2.8$87.93+2.2%$19.70 billion$1.30 billion24.02Earnings Announcement
Gap Up
CureVac logo
CVAC
CureVac
0.7$100.40+6.4%$18.77 billionN/A0.00Increase in Short Interest
Gap Up
Catalent logo
CTLT
Catalent
1.7$107.56+1.3%$18.32 billion$3.09 billion68.51Earnings Announcement
Analyst Upgrade
News Coverage
Elanco Animal Health logo
ELAN
Elanco Animal Health
1.4$32.88+5.6%$15.55 billion$3.07 billion-57.68Earnings Announcement
News Coverage
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
2.0$131.30+0.6%$15.43 billion$219.75 million-16.77Analyst Report
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
2.1$77.77+1.1%$14.21 billion$1.70 billion17.80Insider Selling
Zai Lab logo
ZLAB
Zai Lab
1.6$158.14+1.6%$14.10 billion$12.98 million-52.19Upcoming Earnings
Insider Selling
Grifols logo
GRFS
Grifols
1.3$18.23+1.4%$12.53 billion$5.71 billion16.28Earnings Announcement
Dr. Reddy's Laboratories logo
RDY
Dr. Reddy's Laboratories
1.3$71.02+0.5%$11.81 billion$2.32 billion58.69
Bausch Health Companies logo
BHC
Bausch Health Companies
1.9$28.08+1.1%$10.06 billion$8.60 billion-5.15Earnings Announcement
Analyst Report
Analyst Revision
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
2.1$174.59+1.0%$9.93 billion$2.16 billion55.08Earnings Announcement
Analyst Report
Insider Selling
News Coverage
Maravai LifeSciences logo
MRVI
Maravai LifeSciences
1.6$37.15+4.2%$9.57 billionN/A0.00Upcoming Earnings
Analyst Downgrade
Decrease in Short Interest
Gap Down
United Therapeutics logo
UTHR
United Therapeutics
1.7$195.42+1.7%$8.75 billion$1.45 billion18.49Earnings Announcement
Analyst Report
News Coverage
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.7$114.53+1.0%$7.73 billion$103.71 million-26.09Earnings Announcement
Analyst Upgrade
Insider Selling
Analyst Revision
News Coverage
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
1.6$144.00+4.7%$7.39 billion$3.34 million-18.70Earnings Announcement
News Coverage
Gap Up
BridgeBio Pharma logo
BBIO
BridgeBio Pharma
2.0$48.03+3.2%$7.17 billion$40.56 million-14.09Earnings Announcement
Analyst Report
News Coverage
Gap Up
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.5$132.90+0.0%$7.14 billion$14.98 million-16.19Analyst Revision
News Coverage
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.5$66.38+1.1%$6.91 billion$87.99 million-79.02Earnings Announcement
Analyst Revision
News Coverage
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.3$218.96+0.0%$6.86 billion$311.33 million-127.30Earnings Announcement
Analyst Downgrade
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$74.57+0.1%$5.95 billion$380.83 million-9.54Earnings Announcement
Perrigo logo
PRGO
Perrigo
2.2$42.96+0.7%$5.74 billion$4.84 billion-715.88Upcoming Earnings
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$40.20+0.9%$5.69 billion$150,000.00-18.96Upcoming Earnings
Analyst Revision
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$94.93+1.8%$5.54 billion$66.51 million17.51Analyst Report
Allakos logo
ALLK
Allakos
1.7$100.93+1.8%$5.40 billionN/A-36.84Upcoming Earnings
Analyst Revision
News Coverage
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$36.54+2.2%$5.15 billion$1.12 billion76.13Earnings Announcement
Analyst Report
High Trading Volume
News Coverage
Gap Up
Galapagos logo
GLPG
Galapagos
1.3$75.04+1.5%$4.92 billion$1.00 billion-11.37News Coverage
Gap Up
Schrödinger logo
SDGR
Schrödinger
1.6$68.37+1.7%$4.79 billion$85.54 million0.00Upcoming Earnings
Analyst Downgrade
Insider Selling
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
1.8$71.44+0.9%$4.43 billionN/A-5.82Upcoming Earnings
Analyst Revision
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$75.07+4.0%$4.39 billion$6.87 million-7.25Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Gap Down
I-Mab logo
IMAB
I-Mab
1.2$59.28+0.5%$4.27 billion$4.31 million-2.05Analyst Revision
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$64.79+2.7%$3.93 billion$806.43 million-9.18Earnings Announcement
Analyst Downgrade
Analyst Revision
News Coverage
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$26.23+3.3%$3.91 billion$204.89 million-32.79Analyst Revision
News Coverage
Gap Up
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.5$55.79+1.2%$3.90 billion$117.91 million-11.32Analyst Report
Analyst Revision
LEGN
Legend Biotech
1.3$28.58+2.6%$3.80 billion$64.39 million0.00
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$47.07+1.3%$3.79 billionN/A-6.34Analyst Report
Analyst Revision
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$20.10+7.9%$3.66 billion$114.62 million-8.10Earnings Announcement
Analyst Report
High Trading Volume
News Coverage
Gap Down
Alkermes logo
ALKS
Alkermes
1.2$22.00+0.0%$3.53 billion$1.17 billion-47.83Analyst Report
Insider Selling
High Trading Volume
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.8$114.89+2.9%$3.38 billionN/A-57.16Earnings Announcement
Analyst Upgrade
Analyst Revision
News Coverage
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$21.07+0.6%$3.37 billion$339.08 million-12.25Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Insmed logo
INSM
Insmed
1.2$32.58+0.2%$3.36 billion$136.47 million-12.53Earnings Announcement
Analyst Downgrade
News Coverage
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.2$61.62+1.2%$3.30 billion$1.11 billion19.81Analyst Report
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$64.96+0.3%$3.19 billionN/A-18.51Earnings Announcement
Analyst Downgrade
Analyst Revision
News Coverage
Arvinas logo
ARVN
Arvinas
1.7$63.63+0.8%$3.12 billion$42.98 million-24.86Earnings Announcement
Analyst Upgrade
Unusual Options Activity
Analyst Revision
News Coverage
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$85.06+9.7%$3.08 billion$26.52 million-7.49Earnings Announcement
High Trading Volume
News Coverage
Gap Up
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
0.9$75.47+0.5%$2.89 billion$644.77 million-10.77
Cryoport logo
CYRX
Cryoport
1.5$63.03+2.3%$2.87 billion$33.94 million-108.67Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
This page was last updated on 5/9/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.